AbbVie to Buy Apogee Therapeutics for $10.9 Billion
Bloomberg 2026-06-22 14:12:44
Context: AbbVie, a pharmaceutical company, has agreed to acquire Apogee Therapeutics for $10.9 billion, expanding its presence in the dermatology market. The acquisition adds treatments for atopic dermatitis, also known as eczema, to AbbVie's portfolio. This deal was discussed by Bloomberg Intelligence's Sam Fazeli on "Bloomberg Open Interest."
Key Facts
- AbbVie has agreed to acquire Apogee Therapeutics for a total of $10.9 billion.
- The acquisition enhances AbbVie's presence in dermatology by adding treatments for atopic dermatitis, commonly known as eczema, to its portfolio.
- Bloomberg Intelligence's Sam Fazeli discussed the deal on "Bloomberg Open Interest."
- The deal expands AbbVie's offerings in the dermatology market, specifically in the area of eczema treatments.
- Apogee Therapeutics' treatments for atopic dermatitis will be added to AbbVie's existing portfolio of pharmaceutical products.